title: It is anticipated that as is usually the case, financial motivation will move TZ from its current status “potential anti-MDR/XDR agent,” to one that will cure MDR and XDR TB. Foreword.
authors.affiliation: Unit of Mycobacteriology/UPMM, Institute of Hygiene and Tropical Medicine of Lisbon Universidade Nova de Lisboa
authors.forename: Leonard
authors.initials: L
authors.lastname: Amaral
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D055808:Drug Discovery; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000472:pathogenicity; D013881:Thioridazine / Q000494:pharmacology / Q000627:therapeutic use*; D017211:Treatment Failure; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; D013881:Thioridazine